Effects of diazepam, citalopram, methadone and naloxone on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test

Neuroscience and Biobehavioral Reviews

Volumn 23, Issue 2, 1998, Pages 287-293

  Sams Dodd, Frank ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Antipsychotics; Citalopram; Diazepam; Methadone; Naloxone; Negative symptoms; Positive symptoms; Rat; Schizophrenia; Social behaviour

Indexed keywords

CITALOPRAM; DIAZEPAM; METHADONE; NALOXONE; NEUROLEPTIC AGENT; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ATAXIA; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SOCIAL INTERACTION; SOCIAL ISOLATION; STEREOTYPY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032408291     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(98)00030-X     Document Type: Conference Paper

References (36)

1. Greifenstein F.E., Yoshitake L., DeValut M., Gajewski L.E. A study of 1-aryl cyclo hexyl amine for anesthesia. Anesth. Analg. 37:1958;283-294.
2. Bodi T., Share I., Levy H., Moyer J.H. Clinical trials of phencyclidine (sernyl) in patients with psychoneurosis. Antibiot. Med. Clin. Therapy. 6:1959;79-84.
3. Davies B.M., Beech H.R. The effects of 1-arylcyclohexylamine (sernyl) on twelve normal volunteers. J. Men. Sci. 106:1960;912-914.
4. Ban T.A., Lohrenz J.J., Lehmann H.E. Observations on the action of sernyl - a new psychotropic drug. Can. Psych. Ass. J. 6:1961;150-157.
5. Siegel RK. Phencyclidine and ketamine intoxication a study of 4 populations of recreational users. In: Peterson RC, Stillman RC, editors. National Institute of Drug Abuse Research Monograph #21. Washington DC: NIH Press, 1978. pp. 119-147.
6. Erard R., Luisada P.V., Peele R. The PCP psychosis: prolonged intoxication or drug-precipitated functional illness? J. Psychedel. Drugs. 12:1980;235-251.
7. CarIsson M., CarIsson A. Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schiz. Bull. 16:1990;425-432.
8. Meltzer H.Y. The mechanism of action of novel antipsychotic drugs. Schiz. Bull. 17:1991;263-287.
9. Freed W.J. Glutamatergic mechansims mediating stimulant and antipsychotic drug effects. Neurosci. Biobehav. Rev. 18:1994;111-120.
10. Sams-Dodd F. Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats. Behav. Pharmacol. 6:1995;55-65.
11. Sams-Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in the rat: a possible animal model of schizophrenia. Behav. Pharmacol. 7:1996;3-23.
12. Sams-Dodd F. Effect of novel antipsychotic drugs on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav. Pharmacol. 8:1997;196-215.
13. Castellani S., Giannini A.L., Adams P.M. Effects of naloxone, metenkephalin, and morpine on phencyclidine-induced behavior in the rat. Psychopharmacology. 78:1982;76-80.
14. Vereby K., Kogan M.J., Joseph Mule S. Phencyclidine-induced stereotypy in rats: effects of methadone, apomorphine and naloxone. Psychopharmacology. 75:1981;44-47.
15. File S.E. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J. Neurosci. Meth. 2:1980;219-238.
16. Sams-Dodd F. Automation of the social interaction test by a video tracking system: behavioural effects of repeated phencyclidine treatment. J. Neurosci. Meth. 59:1995;157-168.
17. Castellani S., Adams P.M. Acute and chronic phencyclidine effects on locomotor activity, stereotypy and ataxia in rats. Eur. J. Pharmacol. 73:1981;143-154.
18. Huitema BE. The analysis of covariants and alternatives. New York: Wiley, 1980.
19. Burns R.S., Lemer S.E. Perspectives: acute phencyclidine intoxication. Clin. Toxicol. 9:1976;477-501.
20. Young T., Lawson G.W., Gacono C.B. Clinical aspects of phencyclidine (PCP). Int. J. Add. 22:1987;1-15.
21. Giannini A.L., Loiselle R.H., Price W.A., Giannini M.C. Chlorpromazine vs meperidine in the treatment of phencyclidine psychosis. J. Clin. Psychiat. 46:1985;52-54.
22. Arnt L., Hyttel L., Overø K.F. Prolonged treatment with the specific 5-HT-uptake inhibitor citalopram: effect on dopaminergic and serotonergic functions. Pol. J. Pharmacol. Pharm. 36:1984;221-230.
23. Hyttel J., Arnt J., Bøgesø K., Christensen A.V., Larsen J.-J., Lembøl H.L., Meier E., Sánchez C. Neurochimical and behavioural profile of Lu 17-133, (±)trans-4-[3-(3,4-dichlorophenyl)-indan-l-yl]-1-piperazineethanol, an inhibitor of the uptake of dopamine and noradrenaline. Drug Dev. Res. 13:1988;213-230.
24. Arnt J. Characterization of the discriminative stimulus properties induced by 5-HT1 and 5-HT2 agonists in rats. Pharmacol. Toxicol. 64:1989;165-172.
25. Melia K.F., Spealman R.D. Pharmacological characterization of ht ediscriminative-stimulus effects of GBR 12909. J. Pharmacol. Exp. Therap. 258:1991;626-632.
26. Callahan P.M., Cunningham K.A. Modulation of the discriminative stimulus properties of cocaine by 5-HT1B and 5-HT1C receptors. J. Pharmacol. Exp. Therap. 274:1995;1414-1424.
27. Carroll M.E., Lac S.T., Asencio M., Kragh R. Fluoxetine reduces intraveneous cocaine self-administration in rats. Pharmacol. Biochem. Behav. 35:1990;237-244.
28. Vanover K.E., Nader M.A., Woolverton W.L. Evaluation of the discriminative stimulus and reinforcing effects of sertraline in rhesus monkeys. Pharmacol. Biochem. Behav. 41:1992;789-793.
29. Vartiainen H., Tiihonen L., Putkonen A., Koponen H., Virkkunen M., Hakola P., Letho H. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiat. Scan. 91:1995;348-351.
30. Goff D.C., Midha K.K., Sarid-Segal O., Hubbard J.W., Amico E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology. 117:1995;417-423.
31. Spina E., De Domenico P., Ruello C., Longobardo N., Gitto C., Anione M., Di Rosa A.E., Caputi A.P. Adjunctive fluoxetine in the treatment of negative symptoms in choronic schizophrenic patients. Int. Clin. Psychopharmacol. 9:1994;281-285.
32. Dall'Olio R., Gandolfi O., Montanaro N. Effects of chronic treatment with dizocilpine (MK-801) on the behavioral response to dopamine receptor agonists in the rat. Psychopharmacology. 107:1992;591-594.
33. Martin R., Svensson A., Carlsson A., Carlsson M.L. On the roles of dopamine D-1 vs D-2 receptors for the hyperactivity response elicited by MK-801. J. Neural Transm. 95:1994;113-121.
34. Venna A., Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J. Neurosci. 16:1996;373-379.
35. Sams-Dodd F. Effects of dopamine agonists and antagonists on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Psychopharmacology. 135:1998;182-193.
36. Jackson D.M., Johansson C., Lindgren L.M., Bengtson A. Dopamine receptor anatagonists block amphetamine and phencyclidine-induced motor stimulation in rats. Pharmacol. Biochem. Behav. 41:1994;465-471.